CLINICAL EXPERIENCE WITH CRIZOTINIB IN SPECIAL POPULATIONS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Ahn, M-J [1 ]
Crino, L. [2 ]
Solomon, Ben [3 ]
Zhou, Caicun [4 ]
Ou, Sai-hong I. [5 ]
Selaru, P. [6 ]
Cohen, D. P. [6 ]
Bartlett, C. H. [7 ]
Kim, Dong-wan [8 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Osped S Maria Misericordia, Perugia, Italy
[3] Peter Maccallum Canc Ctr, Melbourne, Vic, Australia
[4] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China
[5] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Med Hematol Oncol, Orange, CA 92668 USA
[6] Pfizer Oncol, La Jolla, CA USA
[7] Pfizer Oncol, New York, NY USA
[8] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 11期
关键词：
poor performance status; brain metastases; elderly; crizotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-036
引用
收藏
页码：S490 / S491
页数：2
相关论文
共 50 条
  • [21] Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patients
    Cui, Shaohua
    Zhao, Yizhuo
    Gu, Aiqin
    Ge, Xiaoxiao
    Song, Yanyan
    Zhang, Wei
    Lou, Yuqing
    Dong, Lili
    Han, Baohui
    Jiang, Liyan
    MEDICAL ONCOLOGY, 2015, 32 (06)
  • [22] EFFICACY AND SAFETY OF CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) RESULTS FROM A PHASE II GLOBAL TRIAL
    Ferreira, Carlos G.
    Barrios, C.
    Shaw, Alice T.
    Shi, Yuankai
    De Pas, Tommaso M.
    Yang, Pan C.
    Riely, Greg J.
    Crino, Lucio
    Iyer, Shrividya
    Polli, Anna
    Lanzalone, Silvana
    Kim, Dong W.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S107 - S108
  • [23] Clinical experience with crizotinib in patients (pts) with advanced ALK plus non-small cell lung cancer (NSCLC) and brain metastases
    Crino, L.
    Ahn, M. J.
    Ou, S. H. I.
    Solomon, B. J.
    Costa, D. B.
    Shreeve, S. M.
    Wiltshire, R.
    Selaru, P.
    Zhou, C.
    Riely, G. J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S800 - S800
  • [24] Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib
    Biagio Ricciuti
    Andrea De Giglio
    Carmen Mecca
    Cataldo Arcuri
    Sabrina Marini
    Giulio Metro
    Sara Baglivo
    Angelo Sidoni
    Guido Bellezza
    Lucio Crinò
    Rita Chiari
    Medical Oncology, 2018, 35
  • [25] Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib
    Ricciuti, Biagio
    De Giglio, Andrea
    Mecca, Carmen
    Arcuri, Cataldo
    Marini, Sabrina
    Metro, Giulio
    Baglivo, Sara
    Sidoni, Angelo
    Bellezza, Guido
    Crino, Lucio
    Chiari, Rita
    MEDICAL ONCOLOGY, 2018, 35 (05)
  • [26] PHASE 2 DATA FOR CRIZOTINIB (PF-02341066) IN ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PROFILE 1005
    Riely, Gregory J.
    Kim, Dong-Wan
    Crino, Lucio
    Janne, Pasi A.
    Blackhall, Fiona H.
    Camidge, David R.
    Hirsh, Vera
    Mok, Tony S. K.
    Solomon, Ben
    Soria, Jean-Charles
    Park, Keunchil
    Gadgeel, Shirish M.
    Martins, Renato G.
    Han, Ji-Youn
    De Pas, Tommaso
    Bottomley, Andrew
    Polli, Anna
    Petersen, Jennifer A.
    Tassell, Vanessa R.
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S411 - S412
  • [27] RESULTS OF A GLOBAL PHASE II STUDY WITH CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)
    Kim, D. -W.
    Ahn, M. -J
    Shi, Y.
    De Pas, T. M.
    Yang, P. -C
    Riely, G. J.
    Crino, L.
    Evans, T. L.
    Liu, X.
    Han, J. -Y.
    Salgia, R.
    Lanzalone, S.
    Polli, A.
    Iyer, S.
    Shaw, A. T.
    ANNALS OF ONCOLOGY, 2012, 23 : 32 - 33
  • [28] Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non-Small Cell Lung Cancer?
    Crystal, Adam S.
    Shaw, Alice T.
    CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4479 - 4481
  • [29] Clinical Outcomes of Crizotinib in Real-World Practice Settings for Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer
    Davis, K. L.
    Lenz, C.
    Houghton, K.
    Kaye, J. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 238 - 239
  • [30] PRELIMINARY EXPOSURE RESPONSE (ER) ANALYSIS OF CRIZOTINIB IN PATIENTS WITH ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER
    French, J.
    Tan, W.
    Kang, D.
    Bello, A.
    Selaru, P.
    Wilner, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S132 - S132
12345